glp-1 drug market competition 2025 Pharma Giants Bet on Next-Generation Treatments to Sustain Growth The United States GLP-1 Receptor

Saving muscle while losing weight: a vital strategy for sustainable results while on GLP-1 related drugs

By July 31, 2025, the FDA had received 605 reports of adverse events tied to compounded semaglutide and 545 reports related to compounded tirzepatide

Diabetes was the eighth leading cause of death in 2021 and drastically affects the quality of life for those who have this disease

Despite concerns over affordability and side effects, in May, analysts at Morgan Stanley Research predicted the global obesity drug market could peak at $150 in 2035, up from the firms previous forecast of $105 billion

As a result, industries that rely on unhealthy habits, such as tobacco and alcohol, could see a decline in demand

This variation in study duration may introduce inconsistency across the studies